Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jean-Frederic Colombel

Showing results (421-430 of 463) with videos related to

Pageof 47
Sort By:
JAMA|December 17, 2015
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical TrialChristopher J Hawkey, Matthieu Allez, Miranda M Clark, et al.
Gastroenterology|March 1, 2022
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial ResultsJulián Panés, Jean-Frederic Colombel, Geert R D'Haens, et al.
Gastroenterology|January 12, 2023
Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative ColitisAlexandra E Livanos, Alexandra Dunn, Jeremy Fischer, et al.
Gastroenterology|July 1, 2018
Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western CountriesShailja C Shah, Hamed Khalili, Corinne Gower-Rousseau, et al.
JAMA|July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical TrialsEdouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Gastroenterology|September 4, 2021
Molecular Characterization of Limited Ulcerative Colitis Reveals Novel Biology and Predictors of Disease ExtensionCarmen Argmann, Minami Tokuyama, Ryan C Ungaro, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Gut|May 4, 2018
Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort studyJoren R Ten Hove, Shailja C Shah, Seth R Shaffer, et al.
Lancet (London, England)|October 16, 2012
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Pageof 47

Showing results (421-430 of 463) with videos related to

Sort By:
Pageof 47
JAMA|December 17, 2015
Autologous Hematopoetic Stem Cell Transplantation for Refractory Crohn Disease: A Randomized Clinical TrialChristopher J Hawkey, Matthieu Allez, Miranda M Clark, et al.
Gastroenterology|March 1, 2022
Higher vs Standard Adalimumab Induction and Maintenance Dosing Regimens for Treatment of Ulcerative Colitis: SERENE UC Trial ResultsJulián Panés, Jean-Frederic Colombel, Geert R D'Haens, et al.
Gastroenterology|January 12, 2023
Anti-Integrin αvβ6 Autoantibodies Are a Novel Biomarker That Antedate Ulcerative ColitisAlexandra E Livanos, Alexandra Dunn, Jeremy Fischer, et al.
Gastroenterology|July 1, 2018
Sex-Based Differences in Incidence of Inflammatory Bowel Diseases-Pooled Analysis of Population-Based Studies From Western CountriesShailja C Shah, Hamed Khalili, Corinne Gower-Rousseau, et al.
JAMA|July 22, 2024
Risankizumab for Ulcerative Colitis: Two Randomized Clinical TrialsEdouard Louis, Stefan Schreiber, Remo Panaccione, et al.
Gastroenterology|September 4, 2021
Molecular Characterization of Limited Ulcerative Colitis Reveals Novel Biology and Predictors of Disease ExtensionCarmen Argmann, Minami Tokuyama, Ryan C Ungaro, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as induction therapy for Crohn's disease: results from the phase 3 ADVANCE and MOTIVATE induction trialsGeert D'Haens, Remo Panaccione, Filip Baert, et al.
Lancet (London, England)|June 1, 2022
Risankizumab as maintenance therapy for moderately to severely active Crohn's disease: results from the multicentre, randomised, double-blind, placebo-controlled, withdrawal phase 3 FORTIFY maintenance trialMarc Ferrante, Remo Panaccione, Filip Baert, et al.
Gut|May 4, 2018
Consecutive negative findings on colonoscopy during surveillance predict a low risk of advanced neoplasia in patients with inflammatory bowel disease with long-standing colitis: results of a 15-year multicentre, multinational cohort studyJoren R Ten Hove, Shailja C Shah, Seth R Shaffer, et al.
Lancet (London, England)|October 16, 2012
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trialDavid Laharie, Arnaud Bourreille, Julien Branche, et al.
Pageof 47